Published in JAMA Intern Med on April 08, 2013
Measuring low-value care in Medicare. JAMA Intern Med (2014) 3.39
Changes in Low-Value Services in Year 1 of the Medicare Pioneer Accountable Care Organization Program. JAMA Intern Med (2015) 3.01
The inferior vena cava filter. JAMA Intern Med (2013) 0.90
Benefit vs. Risk of a Permanent Inferior Vena Cava Filter in Pulmonary Embolism with Anticoagulation Contraindication. Maedica (Buchar) (2013) 0.86
Venous thromboembolism in hematopoietic stem cell transplant recipients. Bone Marrow Transplant (2015) 0.84
Thromboprophylaxis patterns and determinants in critically ill patients: a multicenter audit. Crit Care (2014) 0.83
Primary Nephrotic Syndrome in Adults as a Risk Factor for Pulmonary Embolism: An Up-to-Date Review of the Literature. Int J Nephrol (2014) 0.82
Retrievable inferior vena cava filters can be placed and removed with a high degree of success: Initial experience. Catheter Cardiovasc Interv (2015) 0.79
Indications, applications, and outcomes of inferior vena cava filters for venous thromboembolism in Japanese patients. Heart Vessels (2015) 0.77
Improving the retrieval rate of inferior vena cava filters with a multidisciplinary team approach. J Vasc Surg Venous Lymphat Disord (2016) 0.77
A Dedicated Inferior Vena Cava Filter Service Line: How to Optimize Your Practice. Semin Intervent Radiol (2016) 0.77
IVC filter retrieval in adolescents: experience in a tertiary pediatric center. Pediatr Radiol (2016) 0.77
Massive hemoptysis in a patient with pulmonary embolism, a real therapeutic conundrum. Respir Med Case Rep (2017) 0.75
[Vena cava filters in pulmonary embolism: temporary or permanent?--Cava filters have to be removed early]. Dtsch Med Wochenschr (2013) 0.75
IVC filters-Trends in placement and indications, a study of 2 populations. Medicine (Baltimore) (2017) 0.75
Pathogenesis of Thromboembolism and Endovascular Management. Thrombosis (2017) 0.75
The Role of Inferior Vena Cava Filters in Cancer Patients. Semin Intervent Radiol (2016) 0.75
Retrievable Inferior Vena Cava Filters in Patients with Cancer: Complications and Retrieval Success Rate. Int J Vasc Med (2016) 0.75
Duodenal perforation by an inferior vena cava filter in a polyarteritis nodosa sufferer. Int J Surg Case Rep (2014) 0.75
Hospital Variation and Patient Characteristics Associated With Vena Cava Filter Utilization. Med Care (2017) 0.75
Retrieval of Inferior Vena Cava Filters: Technical Considerations. Semin Intervent Radiol (2016) 0.75
Robotic-Assisted Inferior Vena Cava Filter Retrieval. Methodist Debakey Cardiovasc J (2017) 0.75
Heart block and cardiac embolization of fractured inferior vena cava filter. SAGE Open Med Case Rep (2016) 0.75
Implementation of an institutional protocol to improve inferior vena cava utilization and outcomes. J Thromb Thrombolysis (2017) 0.75
Retrospective analysis of outcomes following inferior vena cava (IVC) filter placement in a managed care population. J Thromb Thrombolysis (2017) 0.75
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.94
The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood (2011) 6.50
Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.88
Systematic overview of warfarin and its drug and food interactions. Arch Intern Med (2005) 5.86
Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med (2011) 4.59
The vexing problem of guidelines and conflict of interest: a potential solution. Ann Intern Med (2010) 3.47
Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med (2013) 3.40
Acute kidney injury after cardiac surgery: focus on modifiable risk factors. Circulation (2009) 3.10
Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost (2011) 2.75
Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood (2011) 2.72
A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med (2013) 2.68
Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. Arch Intern Med (2007) 2.50
Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 2.50
Antiphospholipid syndrome. Lancet (2010) 2.47
Predicting deep venous thrombosis in pregnancy: out in "LEFt" field? Ann Intern Med (2009) 2.26
Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, and outcomes. Chest (2013) 2.24
Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation (2012) 2.16
Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med (2005) 1.87
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol (2012) 1.85
Fresh frozen plasma transfusion in critically ill patients. Crit Care Med (2007) 1.81
Thrombopoietin-receptor agonists for primary immune thrombocytopenia. N Engl J Med (2011) 1.78
Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ (2008) 1.71
Patients with severe sepsis vary markedly in their ability to generate activated protein C. Blood (2004) 1.67
Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med (2002) 1.55
A red blood cell agglutination D-dimer test to exclude deep venous thrombosis in pregnancy. Ann Intern Med (2007) 1.53
Prophylaxis of Thromboembolism in Critical Care (PROTECT) Trial: a pilot study. J Crit Care (2005) 1.50
Non-OO blood type influences the risk of recurrent venous thromboembolism. A cohort study. Thromb Haemost (2013) 1.47
Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. Anesthesiology (2014) 1.47
Fetal-maternal hemorrhage detection in Ontario. Am J Clin Pathol (2003) 1.42
Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest (2005) 1.41
Postpartum management of women at increased risk of thrombosis--results of a Canadian pilot survey. J Rheumatol (2006) 1.40
Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation Forum. Ann Pharmacother (2008) 1.32
Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. Arch Intern Med (2008) 1.28
A diagnostic strategy involving a quantitative latex D-dimer assay reliably excludes deep venous thrombosis. Ann Intern Med (2003) 1.21
Post-thrombotic syndrome in children: a systematic review of frequency of occurrence, validity of outcome measures, and prognostic factors. Haematologica (2010) 1.20
Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment. Am J Hematol (2009) 1.18
The risk of hemorrhage among patients with warfarin-associated coagulopathy. J Am Coll Cardiol (2006) 1.16
Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention. Am J Hematol (2009) 1.11
Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis. Blood (2006) 1.10
JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood (2009) 1.09
Outcome of pregnancy in homozygous sickle cell disease. Obstet Gynecol (2004) 1.08
Natural history of mesenteric venous thrombosis in patients treated with vitamin K antagonists: a multi-centre, retrospective cohort study. Thromb Haemost (2009) 1.07
Comment on: editorial by Husted et al. "Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel". (Thromb Haemost 2014; 111: 781-782). Thromb Haemost (2014) 1.07
Detecting myocardial infarction in critical illness using screening troponin measurements and ECG recordings. Crit Care (2008) 1.03
Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review. J Crit Care (2009) 1.00
Incidence of venous thromboembolism in patients undergoing thoracotomy for lung cancer. J Thorac Cardiovasc Surg (2008) 1.00
Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial. Haematologica (2012) 1.00
Safety of thrombolysis in cerebral venous thrombosis. A systematic review of the literature. Thromb Haemost (2010) 0.97
Iron-Deficiency Anemia. N Engl J Med (2015) 0.97
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue with amyloid deposition: a clinicopathologic case series. Am J Clin Pathol (2012) 0.97
Reversal of target-specific oral anticoagulants. J Thromb Thrombolysis (2013) 0.96
Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors. Crit Care (2008) 0.96
Tailoring warfarin induction doses to reflect individual and disease-specific factors. Am J Med (2005) 0.95
Has the incidence of deep vein thrombosis in patients undergoing total hip/knee arthroplasty changed over time? A systematic review of randomized controlled trials. Thromb Res (2008) 0.93
Dalteparin versus warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysis. Pharmacoeconomics (2006) 0.90
A forgotten cause of kidney injury in chronic myelomonocytic leukemia. Am J Kidney Dis (2009) 0.89
Evidence and clinical judgment: vena cava filters. Thromb Haemost (2014) 0.88
Direct thrombin inhibitors. Thromb Res (2002) 0.88
Prediction scores do not correlate with clinically adjudicated categories of pulmonary embolism in critically ill patients. Can Respir J (2013) 0.87
Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure. J Thromb Thrombolysis (2011) 0.87
Clinically important deep vein thrombosis in the intensive care unit: a survey of intensivists. Crit Care (2004) 0.86
PROphylaxis for ThromboEmbolism in Critical Care Trial protocol and analysis plan. J Crit Care (2011) 0.85
The "parallel-cohort RCT": Novel design aspects and application in the Kids-DOTT trial of pediatric venous thromboembolism. Contemp Clin Trials (2009) 0.85
Targeting anemia with erythropoietin during critical illness. N Engl J Med (2007) 0.85
Impact of thromboprophylaxis guidelines on clinical outcomes following total hip and total knee replacement. Thromb Res (2012) 0.85
Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study. Haematologica (2011) 0.85
Practice patterns for deep vein thrombosis prophylaxis in minimal-access surgery. Can J Surg (2006) 0.84
Red blood cell transfusion and increased length of storage are not associated with deep vein thrombosis in medical and surgical critically ill patients: a prospective observational cohort study. Crit Care (2011) 0.84
The incidence and impact of lupus anticoagulants among patients in the intensive care unit. Saudi Med J (2005) 0.83
Are brand-name and generic warfarin interchangeable? A survey of Ontario patients and physicians. Can J Clin Pharmacol (2005) 0.83
Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease. Br J Haematol (2005) 0.83
Oral cyclic melphalan and dexamethasone for patients with AL amyloidosis. Clin Lymphoma Myeloma Leuk (2010) 0.83
Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis. Thromb Haemost (2016) 0.83
Risk of recurrent venous thromboembolism after a first oestrogen-associated episode. Data from the REVERSE cohort study. Thromb Haemost (2010) 0.83
Thromboprophylaxis patterns and determinants in critically ill patients: a multicenter audit. Crit Care (2014) 0.83
Treatment of warfarin-associated coagulopathy with vitamin K. Expert Rev Hematol (2011) 0.82
Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis. Intensive Care Med (2013) 0.82
Practical aspects of new oral anticoagulant use in atrial fibrillation. Pol Arch Med Wewn (2014) 0.81
Thrombopoietin receptor agonists in primary immune thrombocytopenia. Semin Hematol (2013) 0.81
Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, São Paulo, Brazil. J Thromb Thrombolysis (2011) 0.79
Antiphospholipid antibodies in critical illness. Crit Care Med (2010) 0.79
Effect of chronic kidney disease on red blood cell rheology. Clin Hemorheol Microcirc (2006) 0.79
The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis. Blood Coagul Fibrinolysis (2016) 0.78
Competing Risk Analysis for Evaluation of Dalteparin Versus Unfractionated Heparin for Venous Thromboembolism in Medical-Surgical Critically Ill Patients. Medicine (Baltimore) (2015) 0.78
Low prevalence of JAK2 V617F mutation in patients with first unprovoked venous thromboembolism. Br J Haematol (2011) 0.78
Dabigatran-induced acute hepatitis. Clin Appl Thromb Hemost (2012) 0.78
Treatment with novel oral anticoagulants: indications, efficacy and risks. Curr Opin Hematol (2013) 0.78
The diagnosis of myocardial infarction in critically ill patients: an agreement study. J Crit Care (2009) 0.77
Antiphospholipid syndrome: a challenging hypercoagulable state with systemic manifestations. Hematol Oncol Clin North Am (2010) 0.77
A randomized trial comparing 1 mg of oral vitamin K with no treatment in the management of warfarin-associated coagulopathy in patients with mechanical heart valves. J Am Coll Cardiol (2005) 0.77